placeholder
Importance
62
Trust
80
Urgency
30
REGULATORY · PRIMARY SOURCE
Altru Telehealth, LLC dba Altru Telehealth - 728274 - 06/08/2026
The FDA sent Altru Telehealth a warning letter for making false claims about compounded semaglutide and tirzepatide drugs on its website. The company claimed the drugs were FDA-approved and that compounding pharmacies were FDA-licensed, which is illegal — compounded drugs are not FDA-approved, and pharmacies don't receive FDA licenses.
Analysis
FDA keeps cracking down on telehealth companies selling compounded semaglutide and tirzepatide with false claims. This pushes patients toward brand-name Ozempic and Wegovy from Novo and Lilly.
- FDA sent Altru Telehealth a warning letter dated June 8, 2026 (ref MARCS-CMS 728274)
- Altru claimed compounded semaglutide 'offers the same results but at a fraction of the cost of brand names such as Ozempic, Mounjaro & Wegovy'
- Altru must respond in writing within 15 business days or face seizure and injunction
FDA Drug Approvals & Databases4d
Read